Egalet Corporation announced the appointment of Patrick Shea as chief commercial officer (CCO). Mr. Shea will be responsible for leading company's commercial activities and will report to Bob Radie, company's chief executive officer. In his role Mr. Shea will be responsible for developing and implementing the commercialization strategy for OXAYDO® (oxycodone HCI, USP) tablets for oral use only - CII, SPRIX® (ketorolac tromethamine) Nasal Spray, ARYMO™ ER (morphine sulfate) extended-release tablets which is under review at the U.S. Food and Drug Administration and additional Guardian™ Technology pipeline products as they are developed. Most recently Mr. Shea served as CCO at Clarus Therapeutics Inc.